Terapia ormonale mascolinizzante (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Terapia ormonale mascolinizzante" in Italian language version.

refsWebsite

Global rank Italian rank

11doi.org

2^nd place

7^th place

8nih.gov

4^th place

9^th place

7oadoi.org

799^th place

22^nd place

3books.google.com

3^rd place

14^th place

3worldcat.org

5^th place

26^th place

3unibo.it

4,963^rd place

325^th place

2web.archive.org

1^st place

2ajog.org

low place

1endocrine.org

low place

1drugs.com

399^th place

1,563^rd place

1medscape.com

719^th place

799^th place

1semanticscholar.org

11^th place

2,598^th place

ajog.org

Grimstad FW, Fowler KG, New EP, Ferrando CA, Pollard RR, Chapman G, Gomez-Lobo V, Gray M, Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series., in The American Journal of Obstetrics and Gynecology, vol. 220, n. 3, 2019, pp. 257.E1-E7, DOI:10.1016/j.ajog.2018.12.021, PMID 30579875.
Krempasky C, Harris M, Abern L, Grimstad F, Contraception across the transmasculine spectrum, in The American Journal of Obstetrics and Gynecology, vol. 222, n. 2, 2020, pp. 134–143, DOI:10.1016/j.ajog.2019.07.043, PMID 31394072.

books.google.com

Index Nominum 2000: International Drug Directory, Taylor & Francis, January 2000, pp. 63–, ISBN 978-3-88763-075-1.
Thomas E. Hyde e Marianne S. Gengenbach, Conservative Management of Sports Injuries, Jones & Bartlett Learning, 2007, pp. 1100–, ISBN 978-0-7637-3252-3.
Gianna E. Israel, Donald E. Tarver e Joy Diane Shaffer, Transgender Care: Recommended Guidelines, Practical Information, and Personal Accounts, Temple University Press, 26 April 2001, p. 69, ISBN 978-1-56639-852-7.

doi.org

dx.doi.org

N. M. Nota, C. M. Wiepjes e de Blok CJM, Nota NM, Wiepjes CM, de Blok, C. J. M., Gooren LJG, Kreukels BPC, den Heijer M. "Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy." Circulation (2019)., in Circulation, vol. 139, n. 11, 2019, pp. 1461–1462, DOI:10.1161/CIRCULATIONAHA.118.038584, PMID 30776252.
T. Alzahrani, T. Nguyen e A. Ryan, Alzahrani T, Nguyen T, Ryan A, et al. "Cardiovascular disease risk factors and myocardial infarction in the transgender population." Circ Cardiovasc Qual Outcomes (2019)., in Circ Cardiovasc Qual Outcomes, vol. 12, n. 4, 2019, pp. e005597, DOI:10.1161/CIRCOUTCOMES.119.005597, PMID 30950651.
Dermatologic care of the transgender patient, in Int J Womens Dermatol, vol. 3, n. 1, 2017, pp. 65–67, DOI:10.1016/j.ijwd.2016.11.007, PMID 28492057.
«In addition, oral finasteride may block the development of wanted secondary physical features, including voice change, body hair and composition, and clitoromegaly. Therefore, it is important to ensure that all desired changes are complete before the initiation of treatment with finasteride, which is frequently after 2 years of testosterone use.»
Michael S. Irwig, Is there a role for 5α‐reductase inhibitors in transgender individuals?, in Andrology, 2020, DOI:10.1111/andr.12881, ISSN 2047-2919 (WC · ACNP).
Grimstad FW, Fowler KG, New EP, Ferrando CA, Pollard RR, Chapman G, Gomez-Lobo V, Gray M, Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series., in The American Journal of Obstetrics and Gynecology, vol. 220, n. 3, 2019, pp. 257.E1-E7, DOI:10.1016/j.ajog.2018.12.021, PMID 30579875.
Krempasky C, Harris M, Abern L, Grimstad F, Contraception across the transmasculine spectrum, in The American Journal of Obstetrics and Gynecology, vol. 222, n. 2, 2020, pp. 134–143, DOI:10.1016/j.ajog.2019.07.043, PMID 31394072.
Hulshoff, Cohen-Kettenis, P. T Cohen-Kettenis e N. E M Van Haren, Changing your sex changes your brain: influences of testosterone and estrogen on adult human brain structure, in European Journal of Endocrinology, vol. 155, suppl_1, July 2006, pp. 107–114, DOI:10.1530/eje.1.02248, ISSN 0804-4643 (WC · ACNP). URL consultato il 12 dicembre 2007 (archiviato dall'url originale l'11 aprile 2011).
Laura G. Goetz, Ramanaiah Mamillapalli e Cagdas Sahin, Addition of Estradiol to Cross-sex Testosterone Therapy Reduces Atherosclerosis Plaque Formation in Female ApoE -/- Mice, in Endocrinology, vol. 159, n. 2, 2017, pp. 754–762, DOI:10.1210/en.2017-00884, PMID 29253190.
Polderman K, Induction of insulin resistance by androgens and estrogens, in Journal of Clinical Endocrinology & Metabolism, vol. 79, n. 1, 1994, pp. 265–71, DOI:10.1210/jc.79.1.265.
van Kesteren P, Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones, in Clin Endocrinol, vol. 48, n. 3, 1998, pp. 347–54, DOI:10.1046/j.1365-2265.1998.00396.x.
Laura G. Goetz, Ramanaiah Mamillapalli e Maureen J. Devlin, Cross-sex testosterone therapy in ovariectomized mice: addition of low-dose estrogen preserves bone architecture, in American Journal of Physiology. Endocrinology and Metabolism, vol. 313, n. 5, 1º novembre 2017, pp. E540–E551, DOI:10.1152/ajpendo.00161.2017, ISSN 1522-1555 (WC · ACNP), PMID 28765273.

drugs.com

Drugs.com, https://www.drugs.com/history/aveed.html Titolo mancante per url url (aiuto).

endocrine.org

endocrine.org, http://www.endocrine.org/~/media/endosociety/Files/Publications/Clinical%20Practice%20Guidelines/Endocrine-Treatment-of-Transsexual-Persons.pdf Titolo mancante per url url (aiuto).

medscape.com

Medscape, http://www.medscape.com/viewarticle/821632 Titolo mancante per url url (aiuto).

nih.gov

ncbi.nlm.nih.gov

N. M. Nota, C. M. Wiepjes e de Blok CJM, Nota NM, Wiepjes CM, de Blok, C. J. M., Gooren LJG, Kreukels BPC, den Heijer M. "Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy." Circulation (2019)., in Circulation, vol. 139, n. 11, 2019, pp. 1461–1462, DOI:10.1161/CIRCULATIONAHA.118.038584, PMID 30776252.
T. Alzahrani, T. Nguyen e A. Ryan, Alzahrani T, Nguyen T, Ryan A, et al. "Cardiovascular disease risk factors and myocardial infarction in the transgender population." Circ Cardiovasc Qual Outcomes (2019)., in Circ Cardiovasc Qual Outcomes, vol. 12, n. 4, 2019, pp. e005597, DOI:10.1161/CIRCOUTCOMES.119.005597, PMID 30950651.
Dermatologic care of the transgender patient, in Int J Womens Dermatol, vol. 3, n. 1, 2017, pp. 65–67, DOI:10.1016/j.ijwd.2016.11.007, PMID 28492057.
«In addition, oral finasteride may block the development of wanted secondary physical features, including voice change, body hair and composition, and clitoromegaly. Therefore, it is important to ensure that all desired changes are complete before the initiation of treatment with finasteride, which is frequently after 2 years of testosterone use.»
Grimstad FW, Fowler KG, New EP, Ferrando CA, Pollard RR, Chapman G, Gomez-Lobo V, Gray M, Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series., in The American Journal of Obstetrics and Gynecology, vol. 220, n. 3, 2019, pp. 257.E1-E7, DOI:10.1016/j.ajog.2018.12.021, PMID 30579875.
Krempasky C, Harris M, Abern L, Grimstad F, Contraception across the transmasculine spectrum, in The American Journal of Obstetrics and Gynecology, vol. 222, n. 2, 2020, pp. 134–143, DOI:10.1016/j.ajog.2019.07.043, PMID 31394072.
Laura G. Goetz, Ramanaiah Mamillapalli e Cagdas Sahin, Addition of Estradiol to Cross-sex Testosterone Therapy Reduces Atherosclerosis Plaque Formation in Female ApoE -/- Mice, in Endocrinology, vol. 159, n. 2, 2017, pp. 754–762, DOI:10.1210/en.2017-00884, PMID 29253190.
Laura G. Goetz, Ramanaiah Mamillapalli e Maureen J. Devlin, Cross-sex testosterone therapy in ovariectomized mice: addition of low-dose estrogen preserves bone architecture, in American Journal of Physiology. Endocrinology and Metabolism, vol. 313, n. 5, 1º novembre 2017, pp. E540–E551, DOI:10.1152/ajpendo.00161.2017, ISSN 1522-1555 (WC · ACNP), PMID 28765273.

pubmed.ncbi.nlm.nih.gov

Does Testosterone Treatment Increase Anger Expression in a Population of Transgender Men? Giovanna Motta, Chiara Crespi, Valentina Mineccia, Paolo Riccardo Brustio, Chiara Manieri, Fabio Lanfranco, https://pubmed.ncbi.nlm.nih.gov/29175227/

oadoi.org

N. M. Nota, C. M. Wiepjes e de Blok CJM, Nota NM, Wiepjes CM, de Blok, C. J. M., Gooren LJG, Kreukels BPC, den Heijer M. "Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy." Circulation (2019)., in Circulation, vol. 139, n. 11, 2019, pp. 1461–1462, DOI:10.1161/CIRCULATIONAHA.118.038584, PMID 30776252.
T. Alzahrani, T. Nguyen e A. Ryan, Alzahrani T, Nguyen T, Ryan A, et al. "Cardiovascular disease risk factors and myocardial infarction in the transgender population." Circ Cardiovasc Qual Outcomes (2019)., in Circ Cardiovasc Qual Outcomes, vol. 12, n. 4, 2019, pp. e005597, DOI:10.1161/CIRCOUTCOMES.119.005597, PMID 30950651.
Dermatologic care of the transgender patient, in Int J Womens Dermatol, vol. 3, n. 1, 2017, pp. 65–67, DOI:10.1016/j.ijwd.2016.11.007, PMID 28492057.
«In addition, oral finasteride may block the development of wanted secondary physical features, including voice change, body hair and composition, and clitoromegaly. Therefore, it is important to ensure that all desired changes are complete before the initiation of treatment with finasteride, which is frequently after 2 years of testosterone use.»
Michael S. Irwig, Is there a role for 5α‐reductase inhibitors in transgender individuals?, in Andrology, 2020, DOI:10.1111/andr.12881, ISSN 2047-2919 (WC · ACNP).
Laura G. Goetz, Ramanaiah Mamillapalli e Cagdas Sahin, Addition of Estradiol to Cross-sex Testosterone Therapy Reduces Atherosclerosis Plaque Formation in Female ApoE -/- Mice, in Endocrinology, vol. 159, n. 2, 2017, pp. 754–762, DOI:10.1210/en.2017-00884, PMID 29253190.
Polderman K, Induction of insulin resistance by androgens and estrogens, in Journal of Clinical Endocrinology & Metabolism, vol. 79, n. 1, 1994, pp. 265–71, DOI:10.1210/jc.79.1.265.
Laura G. Goetz, Ramanaiah Mamillapalli e Maureen J. Devlin, Cross-sex testosterone therapy in ovariectomized mice: addition of low-dose estrogen preserves bone architecture, in American Journal of Physiology. Endocrinology and Metabolism, vol. 313, n. 5, 1º novembre 2017, pp. E540–E551, DOI:10.1152/ajpendo.00161.2017, ISSN 1522-1555 (WC · ACNP), PMID 28765273.

semanticscholar.org

van Kesteren P, Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones, in Clin Endocrinol, vol. 48, n. 3, 1998, pp. 347–54, DOI:10.1046/j.1365-2265.1998.00396.x.

unibo.it

acnpsearch.unibo.it

Michael S. Irwig, Is there a role for 5α‐reductase inhibitors in transgender individuals?, in Andrology, 2020, DOI:10.1111/andr.12881, ISSN 2047-2919 (WC · ACNP).
Hulshoff, Cohen-Kettenis, P. T Cohen-Kettenis e N. E M Van Haren, Changing your sex changes your brain: influences of testosterone and estrogen on adult human brain structure, in European Journal of Endocrinology, vol. 155, suppl_1, July 2006, pp. 107–114, DOI:10.1530/eje.1.02248, ISSN 0804-4643 (WC · ACNP). URL consultato il 12 dicembre 2007 (archiviato dall'url originale l'11 aprile 2011).
Laura G. Goetz, Ramanaiah Mamillapalli e Maureen J. Devlin, Cross-sex testosterone therapy in ovariectomized mice: addition of low-dose estrogen preserves bone architecture, in American Journal of Physiology. Endocrinology and Metabolism, vol. 313, n. 5, 1º novembre 2017, pp. E540–E551, DOI:10.1152/ajpendo.00161.2017, ISSN 1522-1555 (WC · ACNP), PMID 28765273.

web.archive.org

Copia archiviata, su WPATH. URL consultato il 18 ottobre 2020 (archiviato dall'url originale il 28 gennaio 2014).
Hulshoff, Cohen-Kettenis, P. T Cohen-Kettenis e N. E M Van Haren, Changing your sex changes your brain: influences of testosterone and estrogen on adult human brain structure, in European Journal of Endocrinology, vol. 155, suppl_1, July 2006, pp. 107–114, DOI:10.1530/eje.1.02248, ISSN 0804-4643 (WC · ACNP). URL consultato il 12 dicembre 2007 (archiviato dall'url originale l'11 aprile 2011).

worldcat.org

Michael S. Irwig, Is there a role for 5α‐reductase inhibitors in transgender individuals?, in Andrology, 2020, DOI:10.1111/andr.12881, ISSN 2047-2919 (WC · ACNP).
Hulshoff, Cohen-Kettenis, P. T Cohen-Kettenis e N. E M Van Haren, Changing your sex changes your brain: influences of testosterone and estrogen on adult human brain structure, in European Journal of Endocrinology, vol. 155, suppl_1, July 2006, pp. 107–114, DOI:10.1530/eje.1.02248, ISSN 0804-4643 (WC · ACNP). URL consultato il 12 dicembre 2007 (archiviato dall'url originale l'11 aprile 2011).
Laura G. Goetz, Ramanaiah Mamillapalli e Maureen J. Devlin, Cross-sex testosterone therapy in ovariectomized mice: addition of low-dose estrogen preserves bone architecture, in American Journal of Physiology. Endocrinology and Metabolism, vol. 313, n. 5, 1º novembre 2017, pp. E540–E551, DOI:10.1152/ajpendo.00161.2017, ISSN 1522-1555 (WC · ACNP), PMID 28765273.